Tagged with r&d

brexit Last week, Roche Boss Severin Schwan expressed concern that Brexit could further slow the UK drug approval process. After the UK’s recent divorce from the EMA, officials are in unknown territory. With only six months until the UK leaves the EU, the UK government has advised drug makers to stockpile…

Hong Kong Prof. Michael Yang, an accomplished scientist and start-up expert, introduces the goals of the fast-growing Biomedical Sciences Department of City University Hong Kong. He unveils the contribution of Hong Kong to the Greater Bay Area in the biomedical field, while analyzing the key elements to change so the region can…

Brexit Despite a myriad of uncertainties around its decision to leave the European Union, the UK still stands as one of the world’s premier life science investment destinations. With heavyweight medical science infrastructure and a well-earned reputation for elite-level innovation, the key industry stakeholders featured in our UK report, explore how…

Turkey Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to life-changing innovation. He also pinpoints MSD’s exceptional and enduring commitment to Turkey, which has led the company to emerge as…

UK One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical research; more than both the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). Simon Gillespie, chief…

UK With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland, president, explains how Canon is able to leverage on the talent available in Scotland and what trends he is observing…

UK Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America, discusses the creation of new, innovative partnership models with stakeholders across the healthcare spectrum, how Amgen is leveraging its biologic…

GSK In a pharmaceutical environment faced with stiffening regulatory regimes, and where mergers and acquisitions become more commonplace, GSK’s diversifications and growth model have long come into question. Historically, Big Pharma would work as a one-stop-shop for medicine solutions covering all therapeutic areas, and over the years, companies opened up new…

Cyprus   Jacqueline Anastassiades has been involved in the development of the Cypriot healthcare sector for more than 10 years as the Managing Director of MSD. With the upcoming healthcare reforms, she brings her expert insights into the key requirements the Cyprus national health system should validate as well as the…

UK Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that…

R&D Portugal has forged a name for itself in terms of early adoption of new technology and ideas; making the country a prime destination for clinical trials as well as a market in which multinational pharma companies can trial innovative new treatments before rolling them out across the continent. “We are…

Biogen After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field where research has met relentless challenges and a series of drug candidates have been unsuccessful. Indeed, the failure rate for Alzheimer’s drugs has been 99.6 percent over the…